

## **COMPANY ANNOUNCEMENT**

21 December 2023

No. 26-2023

# ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19

**BIRKERØD, DENMARK** - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, received notice of the following transactions by persons discharging managerial responsibilities according to MAR art. 19.

Under the EU's Market Abuse Regulation art. 19, ViroGates A/S must notify the Danish Financial Supervisory Authority and publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on trading ViroGates shares if the statutory threshold of 20,000 EUR limit is exceeded.

ViroGates hereby notifies and submits the following transactions of shares in ViroGates:

- Jakob Knudsen, Chief executive officer of ViroGates A/S, exercised subscription rights to shares and received 102,388 shares on 19 December 2023. The subscription for shares was related to the recently completed rights emission in ViroGates A/S.
- Lars Krogsgaard, Non-executive board member of ViroGates A/S, exercised subscription rights to shares and received 342,632 shares on 19 December 2023.
   The subscription for shares was related to the recently completed rights emission in ViroGates.

The notification forms related to the transactions are attached.

ViroGates further confirms that all pre-subscribers of shares, cf. company announcement no. 17-2023 from 9 November 2023, have subscribed and received the number of shares reported.

#### For further information, please contact:

ViroGates A/S: CEO, Jakob Knudsen Tel. (+45) 2226 1355, email: <u>ik@virogates.com</u>

Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: ca@vhcorp.se

### **About ViroGates**

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff as well as to monitor health in the general population.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit <a href="https://www.virogates.com">www.virogates.com</a>.



### Skema, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til dem skal indberettes og offentliggøres

1.	Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne			
a)	Na∨n	Lars Krogsgaard		
2.	Årsag til indberetningen			
a)	Stilling/titel	Member of the Board of Directors		
b)	Første indberetning/æn- dring	Første indberetning		
3.	17A32 SS	Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplat- formen, auktionsholderen eller den auktionstilsynsførende		
a)	Navn	ViroGates A/S		
b)	LEI-kode	5493007TX8XS56RMZD94		
4.		ere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) ype transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktioner		
a)	Beskrivelse af det finar sielle instrument, instru menttypen	AKUEL		
	Identifikationskode	DK0061030574		
b)	Transaktionens art	Køb		
c)	Pris(er) og mængde(r)	Pris(er)  DKK 1,541,844	Mængde(r) 342,632	
d)	Aggregerede oplysninger - Aggregeret mængde - Pris	- 342,632 - DKK 1,541,844		
e)	Dato for transaktionen	2023-12-19		
f)	Sted for transaktionen	Nasdaq First North Growth Market Denmark (DSME)		



### Skema, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til dem skal indberettes og offentliggøres

1.	Nærmere oplysninger om	Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne		
a)	Navn	Jakob Knudsen		
2.	Årsag til indberetningen	en		
a)	Stilling/titel	Chief executive officer		
b)	Første indberetning/æn- dring	Første indberetning		
3.	Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplat- formen, auktionsholderen eller den auktionstilsynsførende			
a)	Navn	ViroGates A/S		
b)	LEI-kode	5493007TX8XS56RMZD94		
4.	Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktioner			
a)	Beskrivelse af det finar sielle instrument, instru menttypen	AKUEL		
	Identifikationskode	DK0061030574		
b)	Transaktionens art	Køb		
c)	Pris(er) og mængde(r)	Pris(er)  DKK 483,097	Mængde(r) 102,388	
d)	Aggregerede oplysninger - Aggregeret mængde - Pris	- 102,388 - DKK 483,097		
e)	Dato for transaktionen	2023-12-19		
f)	Sted for transaktionen	Nasdaq First North Growth Market Denmark (DSME)		